Review of Prospective Trials for Degenerative Cervical Myelopathy.

Clin Spine Surg · Dec 01 2022 · Review

Satin AM, Rush AJ, Derman PB

Texas Back Institute, Plano, TX

Spine

SUMMARY — THE REDUCTIONReview of prospective trials in degenerative cervical myelopathy: noncomparative studies show surgery is safe and effective, even for mild disease, while comparative trials are inconsistent and the optimal approach remains debated.
Abstract, as published

Degenerative cervical myelopathy (DCM) is the leading cause of spinal cord dysfunction in adults. DCM refers to a collection of degenerative conditions that cause the narrowing of the cervical canal resulting in neurological dysfunction. A lack of high-quality studies and a recent increase in public health awareness has led to numerous prospective studies evaluating DCM. Studies evaluating the efficacy of surgical intervention for DCM can be characterized by the presence (comparative) or absence (noncomparative) of a nonoperative control group. Noncomparative studies predominate due to concerns regarding treatment equipoise. Comparative studies have been limited by methodological issues and have not produced consistent findings. More recent noncomparative studies have established the safety and efficacy of surgical intervention for DCM, including mild myelopathy. The optimal surgical intervention for DCM remains controversial. A recent randomized clinical trial comparing dorsal and ventral techniques found similar improvements in patient-reported physical function at early follow-up. Recent prospective studies have enriched our understanding of DCM and helped guide current treatment recommendations.

Featured in the 2026-10-05 issue.

← What Is New in Pediatric Bone Health.Can a Simple Smartphone Be a Cornerstone in School Health Scr… →

The Reduction is a free email digest of newly published orthopaedic literature — a handful of new papers in the subspecialties you choose, each summarized like this one. Subscribe free or browse the archive.